| [1] |
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014,513(7517):202-209. DOI: 10.1038/nature13480.
doi: 10.1038/nature13480
|
| [2] |
Kang WM, Meng QB, Yu JC, et al. Factors associated with early recurrence after curative surgery for gastric cance[J]. World J Gastroenterol, 2015,21(19):5934-5940. DOI: 10.3748/wjg.v21.i19.5934.
doi: 10.3748/wjg.v21.i19.5934
pmid: 26019458
|
| [3] |
Liu L, Yu H, Huang L, et al. Progression-free survival as a surrogate endpoint for overall survival in patients with third-line or later-line chemotherapy for advanced gastric cancer[J]. Onco Targets Ther, 2015,8:921-928. DOI: 10.2147/OTT.S82365.
doi: 10.2147/OTT.S82365
pmid: 25960663
|
| [4] |
Fontanella C, Ongaro E, Bolzonello S, et al. Clinical advances in the development of novel VEGFR2 inhibitors[J]. Ann Transl Med, 2014,2(12):123. DOI: 10.3978/j.issn.2305-5839.2014.08.14.
doi: 10.3978/j.issn.2305-5839.2014.08.14
pmid: 25568876
|
| [5] |
Passot G, Dupré A, Rivoire M, et al. Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model[J]. Clin Transl Oncol, 2012,14(12):931-936. DOI: 10.1007/s12094-012-0888-x.
doi: 10.1007/s12094-012-0888-x
|
| [6] |
Fushida S, Oyama K, Kinoshita J, et al. VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and effcacy of anti-VEGF monoclonal antibody[J]. Onco Targets Ther, 2013,6:1445-1451. DOI: 10.2147/OTT.S51916.
pmid: 24204159
|
| [7] |
Beedie SL, Mahony C, Walker HM, et al. Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model[J]. Sci Rep, 2016,6:30038. DOI: 10.1038/srep30038.
pmid: 27443489
|
| [8] |
Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase Ⅲ trial of apatininb in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J]. J Clin Oncol, 2016,34(13):1448-1454. DOI: 10.1200/JCO.2015.63.5995.
doi: 10.1200/JCO.2015.63.5995
pmid: 26884585
|
